King Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer, has voluntarily recalled all dosages of a combination morphine sulfate and naltrexone hydrochloride (Embeda Extended Release Capsules CII) from wholesalers and retailers in the United States because "a prespecified stability requirement was not met during routine testing," a message on the product's Website notes.
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) with presumed inflammatory and degenerative elements. MS entered the rather small ranks of neurologic diseases with disease-modifying therapies in 1993. Since then, 6 agents have received regulatory approval. Five of these agents are indicated for treatment of the relapsing forms of MS and 1 agent for more severe, worsening forms. No therapy is approved or has shown efficacy in treating primary progressive MS. All of the currently available agents are immunomodulatory, strongly supporting the evidence that the pathogenesis of MS relates to an immune aberration. MS has much in common with autoimmune diseases of other organs; although there are abundant data supporting a dysimmune state in patients with MS, the proof of autoimmunity is not yet available. The successful employment of immunomodulating therapies also raises questions about the potential role of other putative causes for MS. Although it had been hoped that increased knowledge of the immunopathogenesis of MS would lead to more focused therapies, that goal has only been partially realized.
What are the mechanisms of cough caused by angiotensin-converting enzyme inhibitors, beta-blockers, and calcium channel blockers, and how can this adverse effect be managed?
The US Food and Drug Administration (FDA) has approved the use of belimumab (Benlysta, Human Genome Sciences and GlaxoSmithKline) in combination with standard therapies to treat active autoantibody-positive systematic lupus erythematosus.
What is the risk to the unborn baby of proton pump inhibitor therapy during pregnancy? Should these drugs be avoided altogether in pregnant women?
Hello. This is Jeffrey Burns from the University of Pennsylvania School of Medicine in Philadelphia. I am Editor-in-Chief of Medscape Nephrology.
Shashi Amur; Issam Zineh; Darrell R Abernethy; Shiew-Mei Huang; Lawrence J Lesko
The US Food and Drug Administration (FDA) has approved the first low-dose oral contraceptive regimen to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75-mg ferrous fumarate placebo tablets.
Paolo Raggi, MD: Hello, I'm Dr. Paolo Raggi. I'm a Professor of Medicine at Emory University School of Medicine in Atlanta, Georgia. It is my pleasure to welcome you to this Medscape CME/CE activity entitled Are We Doing More Harm Than Good? New Perspectives on Calcium Balance in Chronic Kidney Disease (CKD). I'm honored to introduce my friend and colleague, Dr. David Bushinsky, Professor and Chief of Nephrology at the University of Rochester Medical Center in Rochester, New York. Welcome to today's program, David.
David Bushinsky, MD: Hello. It's a pleasure to be here.
之前也有跟各位提過脊隨注射：
Case Presentation
A 61-year-old white man presents with a history of recent lower extremity pain.
The patient was diagnosed with multiple myeloma 26 months before admission and subsequently received multiple rounds of chemotherapy, including neurotoxic bortezomib and vincristine. He reports increasing bilateral lower extremity pain beginning roughly 6 months earlier, described as burning and numbing in nature. He also complains of severe sensitivity of the plantar aspect of his feet, making ambulation difficult. He has been evaluated by a neurologist and underwent an electromyographic (EMG) scan that demonstrates a mixed peripheral neuropathy and lumbar radiculopathy. Spinal magnetic resonance imaging (MRI) demonstrates multilevel lumbar degeneration. The neurosurgical consult states that the patient is not an operative candidate because of his diffuse disease. In addition, he has a history of cardiomyopathy.
October 20, 2010 — Prescribing information for gonadotropin-releasing hormone (GnRH) agonists, which are a class of drugs primarily used to treat prostate cancer, will now bear a warning about the potential risk for heart disease and diabetes in men treated with these medications, the US Food and Drug Administration (FDA) announced today.
October 13, 2010 — Bisphosphonates approved for the treatment of osteoporosis will now bear a label warning about the risk for 2 types of atypical femur fractures, the US Food and Drug Administration (FDA) announced today.
October 8, 2010 — Abbott Laboratories has withdrawn the obesity drug sibutramine (Meridia) from the market in light of clinical trial data pointing to an increased risk for stroke and myocardial infarction, the US Food and Drug Administration (FDA) announced today.
醫藥類 (14) 電腦知識 (3) 心情點滴 (3) 部落格摘要 (1) 其他知識 (1)
或請google "Mulicia"
